1887

Abstract

Empirical evidence suggests that L. treats enteric infections, including dysentery, cholera, and acute infectious gastroenteritis.

The aim of this study is to clarify the growth-inhibitory effects of L. extract against 56 strains of intestinal pathogens.

‘Gogyo-so-cha (GSC)’ was used as the L. formulation. A growth curve analysis was used to measure the growth-inhibitory effects of GSC, and Shiga toxin induction was measured using the latex agglutination test.

GSC demonstrated strong bactericidal effects against and strains from various isolates. GSC demonstrated weak or no bactericidal effects against intestinal commensal bacteria, including spp. and . GSC did not induce toxins.

GSC significantly inhibited the growth of intestinal pathogens, including and , without adversely affecting the intestinal flora, supporting the usage of GSC in traditional Chinese medicine. Taken together, GSC would be of immense value in the developing world, where diarrhoeal infectious diseases continue to pose a major health risk.

Loading

Article metrics loading...

/content/journal/acmi/10.1099/acmi.0.000208
2021-02-24
2021-04-19
Loading full text...

Full text loading...

/deliver/fulltext/acmi/3/3/acmi000208.html?itemId=/content/journal/acmi/10.1099/acmi.0.000208&mimeType=html&fmt=ahah

References

  1. Jialin T. Chinese Materia Medica China: People’s Medical Publishing House; 2007
    [Google Scholar]
  2. von Seidlein L, Kim DR, Ali M, Lee H, Wang X et al. A multicentre study of Shigella diarrhoea in six Asian countries: disease burden, clinical manifestations, and microbiology. PLoS Med 2006; 3:e353 [CrossRef][PubMed]
    [Google Scholar]
  3. WHO Who cholera fact sheet,; 2017
  4. Bielaszewska M, Idelevich EA, Zhang W, Bauwens A, Schaumburg F et al. Effects of antibiotics on Shiga toxin 2 production and bacteriophage induction by epidemic Escherichia coli O104:H4 strain. Antimicrob Agents Chemother 2012; 56:3277–3282 [CrossRef][PubMed]
    [Google Scholar]
  5. Herold S, Karch H, Schmidt H. Shiga toxin-encoding bacteriophages--genomes in motion. Int J Med Microbiol 2004; 294:115–121 [CrossRef][PubMed]
    [Google Scholar]
  6. Atia A, Buchman AL. Treatment of cholera-like diarrhoea with oral rehydration. Ann Trop Med Parasitol 2010; 104:465–474 [CrossRef][PubMed]
    [Google Scholar]
  7. IDSA Antibiotic resistance fact sheet,; 2013
  8. Sur D, Manna B, Niyogi SK, Ramamurthy T, Palit A et al. Role of probiotic in preventing acute diarrhoea in children: a community-based, randomized, double-blind placebo-controlled field trial in an urban slum. Epidemiol Infect 2011; 139:919–926 [CrossRef][PubMed]
    [Google Scholar]
  9. Murakami J, Kishi K, Hirai K, Hiramatsu K, Yamasaki T et al. Macrolides and clindamycin suppress the release of Shiga-like toxins from Escherichia coli O157:H7 in vitro. Int J Antimicrob Agents 2000; 15:103–109 [CrossRef][PubMed]
    [Google Scholar]
  10. Seyama S, Nishioka H, Nakaminami H, Nakase K, Wajima T et al. Evaluation of in vitro bactericidal activity of 1.5% Olanexidine gluconate, a novel biguanide antiseptic agent. Biol Pharm Bull 2019; 42:512–515 [CrossRef][PubMed]
    [Google Scholar]
  11. Yamada T, Wajima T, Nakaminami H, Kobayashi K, Ikoshi H et al. The modified Gingyo-san, a Chinese herbal medicine, has direct antibacterial effects against respiratory pathogens. BMC Complement Altern Med 2016; 16:463 [CrossRef][PubMed]
    [Google Scholar]
  12. Rahimi VB, Ajam F, Rakhshandeh H, Askari VR. A pharmacological review on Portulaca oleracea L.: focusing on anti-inflammatory, anti- oxidant, immuno-modulatory and antitumor activities. J Pharmacopuncture 2019; 22:7–15 [CrossRef][PubMed]
    [Google Scholar]
  13. Zhou Y-X, Xin H-L, Rahman K, Wang S-J, Peng C et al. Portulaca oleracea L.: a review of phytochemistry and pharmacological effects. Biomed Res Int 2015; 2015:92563111 [CrossRef][PubMed]
    [Google Scholar]
  14. Lei X, Li J, Liu B, Zhang N, Liu H. Separation and Identification of Four New Compounds with Antibacterial Activity from Portulaca oleracea L. Molecules 2015; 20:16375–16387 [CrossRef][PubMed]
    [Google Scholar]
  15. Jackson JJ, Kropp H. Beta-Lactam antibiotic-induced release of free endotoxin: in vitro comparison of penicillin-binding protein (PBP) 2-specific imipenem and PBP 3-specific ceftazidime. J Infect Dis 1992; 165:1033–1041 [CrossRef][PubMed]
    [Google Scholar]
  16. Ochoa TJ, Chen J, Walker CM, Gonzales E, Cleary TG. Rifaximin does not induce toxin production or phage-mediated lysis of Shiga toxin-producing Escherichia coli . Antimicrob Agents Chemother 2007; 51:2837–2841 [CrossRef][PubMed]
    [Google Scholar]
  17. Wajima T, Kinugawa R, Yamada T, Ikoshi H, Noguchi N. Panax notoginseng extract possesses significant antibacterial activity against pathogenic streptococci. Pharmacology 2019; 103:221–227 [CrossRef][PubMed]
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/acmi/10.1099/acmi.0.000208
Loading
/content/journal/acmi/10.1099/acmi.0.000208
Loading

Data & Media loading...

Most cited this month Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error